BIIB Q1 2017 Earnings — Biogen Inc. Revenue & Financial Results | Market Cap Arena

BIIBBiogen Inc.

$28B

Q1 2017 Earnings

Healthcare Drug Manufacturers - General

Income Statement

Revenue

$2.8B+3.1% YoY

Gross Profit

$2.4B86.3% margin

Operating Income

$1.0B36.5% margin

Net Income

$748M26.6% margin

EPS (Diluted)

$3.46

QoQ Revenue Growth

-2.1%

Cash Flow

Operating Cash Flow

$235M

Free Cash Flow

-$830M

Stock-Based Comp.

$37M

Balance Sheet

Total Assets

$21.2B

Total Liabilities

$9.7B

Stockholders' Equity

$11.5B

Cash & Equivalents

$924M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$2.8B	$2.7B	+3.1%
Gross Profit	$2.4B	$2.4B	+0.5%
Operating Income	$1.0B	$1.4B	-25.7%
Net Income	$748M	$971M	-23.0%

Revenue Segments

Hemophilia Products

$74M100%